Most patients who become critically ill following infection with SARS-CoV-2, the virus that causes COVID-19, develop acute respiratory distress syndrome (ARDS). New research from John Lambris, PhD, a professor of Pathology and Laboratory Medicine, reports on the successful treatment of a COVID-19 patient suffering from ARDS with complement inhibitor AMY-101. Complement is an integral component of the immune response to viruses and an instigator of inflammation, and evidence suggests that overactive immune response and inflammation are a major cause of severe complications from the virus. The drug AMY-101 inhibits complement, and this study suggests it might be a viable treatment for critically ill COVID-19 patients.
Read more in Clinical Immunology →
